Bio-Rad Laboratories Class A
About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Employees: 7,700
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2.25% more ownership
Funds ownership: 81.88% [Q4 2024] → 84.13% (+2.25%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]
4% less call options, than puts
Call options by funds: $3.6M | Put options by funds: $3.77M
6% less funds holding
Funds holding: 445 [Q4 2024] → 420 (-25) [Q1 2025]
18% less repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 160
20% less first-time investments, than exits
New positions opened: 68 | Existing positions closed: 85
24% less capital invested
Capital invested by funds: $6.17B [Q4 2024] → $4.67B (-$1.49B) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Wells Fargo Brandon Couillard | 6%upside $245 | Equal-Weight Maintained | 9 Jun 2025 |
UBS Dan Leonard | 34%upside $310 | Buy Maintained | 2 May 2025 |
Citigroup Patrick Donnelly | 51%upside $350 | Buy Maintained | 2 May 2025 |
RBC Capital Conor McNamara | 69%upside $392 | Outperform Maintained | 2 May 2025 |
Financial journalist opinion









